AVEO Pharmaceuticals, Inc. (AVEO): Price and Financial Metrics

AVEO Pharmaceuticals, Inc. (AVEO): $14.87

0.01 (+0.07%)

POWR Rating

Component Grades













Add AVEO to Watchlist
Sign Up

Industry: Biotech



in industry


  • AVEO scores best on the Growth dimension, with a Growth rank ahead of 88.07% of US stocks.
  • The strongest trend for AVEO is in Sentiment, which has been heading up over the past 179 days.
  • AVEO's current lowest rank is in the Momentum metric (where it is better than 4.56% of US stocks).

AVEO Stock Summary

  • AVEO PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 84.45% of US listed stocks.
  • Revenue growth over the past 12 months for AVEO PHARMACEUTICALS INC comes in at 269.37%, a number that bests 96.65% of the US stocks we're tracking.
  • The volatility of AVEO PHARMACEUTICALS INC's share price is greater than that of 92.74% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to AVEO PHARMACEUTICALS INC, a group of peers worth examining would be DNAY, HSTO, RNWK, BJDX, and NURO.
  • Visit AVEO's SEC page to see the company's official filings. To visit the company's web site, go to www.aveooncology.com.

AVEO Valuation Summary

  • In comparison to the median Healthcare stock, AVEO's price/sales ratio is 242.11% higher, now standing at 6.5.
  • AVEO's price/sales ratio has moved down 5.5 over the prior 154 months.

Below are key valuation metrics over time for AVEO.

Stock Date P/S P/B P/E EV/EBIT
AVEO 2022-11-01 6.5 16.7 -14.1 -15.2
AVEO 2022-10-31 6.5 16.7 -14.1 -15.2
AVEO 2022-10-28 6.5 16.7 -14.2 -15.2
AVEO 2022-10-27 6.5 16.7 -14.1 -15.2
AVEO 2022-10-26 6.5 16.7 -14.1 -15.2
AVEO 2022-10-25 6.5 16.7 -14.2 -15.2

AVEO Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 101.68%.
  • Its year over year net cashflow from operations growth rate is now at -5.63%.
  • Its 5 year cash and equivalents growth rate is now at 55.39%.
Over the past 33 months, AVEO's revenue has gone up $65,524,000.

The table below shows AVEO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 94.319 -22.661 -29.039
2022-06-30 79.043 -30.927 -36.141
2022-03-31 61.295 -47.142 -41.419
2021-12-31 42.295 -57.257 -53.342
2021-09-30 25.535 -57.953 -57.591
2021-06-30 13.962 -55.768 -55.616

AVEO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AVEO has a Quality Grade of D, ranking ahead of 14.08% of graded US stocks.
  • AVEO's asset turnover comes in at 0.147 -- ranking 224th of 682 Pharmaceutical Products stocks.
  • LXRX, SEEL, and OTLK are the stocks whose asset turnover ratios are most correlated with AVEO.

The table below shows AVEO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.147 0.931 -1.982
2021-03-31 0.083 0.981 -2.596
2020-12-31 0.095 1.000 -2.215
2020-09-30 0.099 1.000 -1.463
2020-06-30 0.499 1.000 -0.212
2020-03-31 0.587 1.000 0.334

AVEO Price Target

For more insight on analysts targets of AVEO, see our AVEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.12 (Strong Buy)

AVEO Stock Price Chart Interactive Chart >

Price chart for AVEO

AVEO Price/Volume Stats

Current price $14.87 52-week high $14.95
Prev. close $14.86 52-week low $3.06
Day low $14.84 Volume 311,100
Day high $14.87 Avg. volume 543,566
50-day MA $12.05 Dividend yield N/A
200-day MA $7.29 Market Cap 516.93M

AVEO Pharmaceuticals, Inc. (AVEO) Company Bio

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

AVEO Latest News Stream

Event/Time News Detail
Loading, please wait...

AVEO Latest Social Stream

Loading social stream, please wait...

View Full AVEO Social Stream

Latest AVEO News From Around the Web

Below are the latest news stories about AVEO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AVEO as an investment opportunity.

uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

Yahoo | November 23, 2022

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

Yahoo | November 23, 2022

bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

Yahoo | November 22, 2022

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

Yahoo | November 18, 2022

Inhibrx (INBX) Down on Updated Data From Bone Cancer Study

Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.

Yahoo | November 18, 2022

Read More 'AVEO' Stories Here

AVEO Price Returns

1-mo 0.68%
3-mo 83.81%
6-mo N/A
1-year 128.77%
3-year 109.44%
5-year -50.27%
YTD 217.06%
2021 -18.72%
2020 -7.58%
2019 -60.98%
2018 -42.65%
2017 416.67%

Continue Researching AVEO

Here are a few links from around the web to help you further your research on Aveo Pharmaceuticals Inc's stock as an investment opportunity:

Aveo Pharmaceuticals Inc (AVEO) Stock Price | Nasdaq
Aveo Pharmaceuticals Inc (AVEO) Stock Quote, History and News - Yahoo Finance
Aveo Pharmaceuticals Inc (AVEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8834 seconds.